Use of high doses of folic acid supplements in pregnant women in Spain: an INMA cohort study

Eva María Navarrete-Muñoz,1,2 Desirée Valera-Gran,1 Manoli García de la Hera,1,2 Daniel Gimenez-Monzo,1 Eva Morales,2,3 Jordi Julve,2,3 Isolina Riaño,2,4 Adonina Tardón,2,5 Jesus Ibarluzea,2,6,7 Loreto Santa-Marina,2,6,7 Mario Murcia,2,8 Marisa Rebagliato,2,9 Jesus Vioque,1,2 on behalf of the INMA Project

ABSTRACT

Objectives: We examined the use of low (<400 µg/day, including no use) and high folic acid supplement (FAS) dosages (≥1000 µg/day) among pregnant women in Spain, and explored factors associated with the use of these non-recommended dosages.

Design: Population-based cohort study.

Setting: Spain.

Participants: We analysed data from 2332 pregnant women of the INMA study, a prospective mother-child cohort study in Spain.

Main outcome measures: We assessed usual dietary folate intake and the use of FAS from preconception to the 3rd month (first period) and from the 4th to the 7th month (second period), using a validated food frequency questionnaire. We used multinomial logistic regression to estimate relative risk ratios (RRRs).

Results: Over a half of the women used low dosages of FAS in the first and second period while 29% and 17% took high dosages of FAS, respectively. In the first period, tobacco smoking (RRR=1.63), alcohol intake (RRR=1.40), multiparous (RRR=1.44), unplanned pregnancy (RRR=4.20) and previous spontaneous abortion (RRR=0.58, lower use of high FAS dosages among those with previous abortions) were significantly associated with low FAS dosages. Alcohol consumption (RRR=1.42), unplanned pregnancy (RRR=2.66) and previous spontaneous abortion (RRR=0.68) were associated with high dosage use. In the second period, only tobacco smoking was significantly associated with high FAS dosage use (RRR=0.67).

Conclusions: A high proportion of pregnant women did not reach the recommended dosages of FAS in periconception and a considerable proportion also used FAS dosages ≥1000 µg/day. Action should be planned by the Health Care System and health professionals to improve the appropriate periconceptional use of FAS, taking into consideration the associated factors.

BACKGROUND

The benefits of periconceptional use of folic acid supplements (FAS) to prevent neural tube defects (NTDs) have been well established since the early 1990s.1 2 Health authorities recommend that all women who plan to become pregnant should take a daily dose of 400 µg FAS and appropriate dietary folate intake from before conception to the third month of pregnancy to reduce the risk of NTDs, while not exceeding the tolerable upper intake level of 1000 µg/day.3 An exception is made for those women with diabetes, epilepsy and history of NTDs, who are recommended to take a daily dose of 5000 µg FAS.4 Although FAS are safe and almost free of toxicity, a few studies have drawn attention to the possible adverse effects of using high doses throughout pregnancy,5-8 and at other stages of life.9

The interest in the health implications of taking FAS has increased recently. Regarding pregnancy, several studies have suggested that FAS use may be an important protective factor for some birth outcomes such as placental abruption, spontaneous abortion, stillbirth, preterm delivery, adverse fetal growth and preeclampsia.10 11 FAS use during pregnancy has been also associated with prevention against impaired neurodevelopment,12 13 but we have recently observed that FAS dosages above the recommendation might affect psychomotor development at 1 year of age.5 Several studies have found a relationship between FAS and allergic disorders or asthma in childhood,14 although a recent meta-analysis does not provide a conclusive
We use data from 2332 pregnant women recruited in Population MATERIALS AND METHODS FAS in the two periods. Seventh month of pregnancy. We also explore factors women in Spain from 3 months before conception to different regions of Spain with a common protocol: INMA Project (INFancia y Medio Ambiente (Childhood and Environment)) between 2003 and 2008 in four dif-

fants and Environment)) between 2003 and 2008 in four different regions of Spain with a common protocol: Valencia, Sabadell (Catalonia), Asturias and Guipuzcoa (Basque Country).21 Women were enrolled during their first antenatal care visit to the main public hospital or health centre of reference. A total of 2644 women who fulfilled the inclusion criteria (≥16 years old, singleton pregnancy, intention to deliver at the reference hospital, no communication handicap and no assisted pregnancy) agreed to participate. Excluding the women who withdrew from the study, those lost to follow-up and those who had an induced or spontaneous abortion, or who had fetal deaths (n=138), a total sample of 2506 women delivered a live infant between May 2004 and August 2008. After excluding participants with missing data for relevant variables, 2332 (93.1%) were included in the present analysis. All participants provided informed consent, and the ethics committees of the centres involved in the study approved the research protocol.

MATERIALS AND METHODS Population

We use data from 2332 pregnant women recruited in the multicentre population-based mother–child cohort INMA Project (INFancia y Medio Ambiente (Childhood and Environment)) between 2003 and 2008 in four different regions of Spain with a common protocol: Valencia, Sabadell (Catalonia), Asturias and Guipuzcoa (Basque Country).21 Women were enrolled during their first antenatal care visit to the main public hospital or health centre of reference. A total of 2644 women who fulfilled the inclusion criteria (≥16 years old, singleton pregnancy, intention to deliver at the reference hospital, no communication handicap and no assisted pregnancy) agreed to participate. Excluding the women who withdrew from the study, those lost to follow-up and those who had an induced or spontaneous abortion, or who had fetal deaths (n=138), a total sample of 2506 women delivered a live infant between May 2004 and August 2008. After excluding participants with missing data for relevant variables, 2332 (93.1%) were included in the present analysis. All participants provided informed consent, and the ethics committees of the centres involved in the study approved the research protocol.

Study variables

Assessment of dietary folate intake and FAS use

FAS and dietary folate were retrospectively assessed by personal interviews at two time points in pregnancy: at 10–13 weeks and at 28–32 weeks; more details about these intakes were described previously.22 Dietary folate intake was determined using a 101-item, semiquantitative food frequency questionnaire (FFQ), covering intakes in two periods. The first period included intakes from the last menstrual period until the third month of pregnancy, and the second period covered intakes from the fourth month to the seventh month of pregnancy. The FFQ was an adapted version of the Willett questionnaire,23 validated and developed for Spanish pregnant women in Valencia.24 In a validation study of the FFQ carried out within the same population of pregnant women in the third month of pregnancy, the correlation coefficient between serum folate and the intake of dietary folate and FAS was satisfactory, r=0.58 (p<0.001).24

Folate content of food items was primarily obtained from food composition tables of the US Department of Agriculture25 and other tables published for Spanish foods.26 In Spain, folate fortification is not mandatory, thus we obtained the folate content of foods from non- fortified foods; except for cereals, owing to the main brands usually fortifying them. The consumption level of FAS or vitamin/mineral preparations containing FAS was collected using a structured questionnaire. FAS were estimated based on supplement brand name and composition, daily dose and timing of consumption. There were three main sources of FAS in Spain: specific single folic acid preparations with content from 400 µg (Zolicco) to 10 000 µg (ASPOL); supplements of levofolate or calcium folate with content between 2500 µg (Folaxin 2.5®) and 15 000 µg/day (Lederfoli); and multivitamins with folic acid content between 75 µg (Calcinaralobs) and 1000 µg (Gestamater). With this information, mean daily FAS intake was estimated as the mean of FAS intake in two periods: the first period included the information of FAS from 3 months before conception to the third month of pregnancy (interview at 10–13 weeks) and the second period included the information of FAS from fourth to seventh month of pregnancy (interview at 28–32 weeks). FAS intake in the two periods was classified into three categories: <400 (including no use), 400–999 and ≥1000 µg/day.

Covariates

Information on covariates was obtained from questionnaires completed by personal interviews in the first and third trimester of pregnancy. The sociodemographic characteristics considered were: maternal age, maternal and paternal education level (primary school or less, secondary school and university studies), lifestyle variables such as tobacco smoking (yes or no), alcohol consumption (yes or no) in the first trimester of pregnancy, and self-reported pre-pregnancy body mass index calculated in kg/m² and classified as <25, 25–29.9 (overweight) and ≥30 (obesity). Relevant data about obstetrics such as number of previous pregnancies (0 and ≥1), unplanned pregnancy (yes or no), previous abortion (yes or no) and visiting a private gynaecologist in the first trimester (yes or no) were also collected.

Statistical analysis

Descriptive analysis of sociodemographic, lifestyle and obstetric characteristics of the pregnant women was...
performed for the four areas of study. We also described the dietary folate and FAS intake overall and by geographical area using geometrical mean, mean and SDs. We used the analysis of variance test for quantitative variables and the χ² test for qualitative variables.

Predictors of the use of low (<400 µg/day, including non-users) and high (≥1000 µg/day) dosages of FAS from preconception to the third month, from the fourth to the seventh month of pregnancy and in the entire pregnancy were explored using multivariate multinomial logistic regression (relative risk ratio: RRR): low-dose or high-dose categories were compared to the recommended dose (400–999 µg/day) adjusted for all other covariates by study areas. We used meta-analysis to obtain combined estimates for the four cohorts. Heterogeneity was quantified by means of the (I²) statistic and p value of heterogeneity test. With levels above 50%, the random-effects model was applied to obtain combined estimates and the fixed effect meta-analysis model when I²<50%. Statistical analyses were conducted with R 3.0.0 (R Foundation for Statistical Computing, Vienna, Austria; http://www.r-project.org).

RESULTS

Table 1 shows the sociodemographic, lifestyle and obstetric characteristics of the pregnant women. Significant differences among geographical areas were observed for most variables although not for parity and previous abortions. Half of the pregnant women were above 30 years of age (Asturias showed the highest proportion, 59.7%, and Valencia the lowest proportion, 43.2%). Of the women, 34.4% reported having pursued university studies. Tobacco smoking and alcohol consumption during the first trimester of pregnancy were reported by 18.1% and 29.9% of the women, respectively. The prevalence of pre-pregnancy obesity was 8.0%. A total of 16.7% of pregnancies were unplanned and previous abortions were reported by 23.5% of the women.

The mean daily folate intake was similar in the two periods of pregnancy, 307.8 and 304.7 µg/day, respectively. The main food group sources of dietary folate intake among the pregnant women in both periods of pregnancy were vegetables (22.8%), fruits (15.7%), legumes (10.5%), dairy products (8.6%) and cereals/pasta (7.0%). Individually, the major contributing foods to dietary folate intake were legumes (10.5%), lettuce (8.4%), oranges (5.5%), bread (5.5%) and cereals (5.5%).

Figure 1 shows the proportion of women using FAS during pregnancy. The percentage of women using FAS in preconception, the first, second and third month of pregnancy was 22.8%, 30.4%, 57.4% and 85.8%, respectively. The proportion of women using FAS in the periconceptional period was similar in the four geographical areas although significant differences were noted afterwards: women in Valencia and Asturias continued using FAS after the third month (84% and 95%, respectively), while most women in Guipuzcoa and Sabadell stopped (approximately 10% continued). Overall, 149 of the women did not take FAS at any time during pregnancy; most were from Sabadell and Guipuzcoa (89%). Considering the entire pregnancy, approximately one-third of the women reported the use of high dosages of FAS (≥1000 µg/day), although this proportion varied by geographical area: Asturias and Guipuzcoa showed higher percentages of women using FAS dosages ≥1000 µg/day than women from Sabadell and Valencia (data not show). The major sources of high dosages of FAS (≥1000 µg/day) were specific single folic acid preparations such as ACFOL (5000 µg/day) or ASPOL (10 000 µg/day).

Overall, during the periconceptional stage, 57% of pregnant women used low FAS dosages (<400 µg/day, including no use), and 29% of women used high FAS dosages (≥1000 µg/day). In this period, the mean daily intake of FAS was 433.0 µg/day for women classified as taking FAS dosages of 400–999 µg/day, 141.8 µg/day for women taking FAS dosages <400 µg/day and 3104.6 µg/day for women taking dosages of ≥1000 µg/day. Table 2 shows multivariate analyses for all the cohorts combined, in the first period. Tobacco smoking (RRR=1.63) and alcohol intake (RRR=1.40) in the first trimester of pregnancy, unplanned pregnancy (RRR=4.20), previous pregnancies (RRR=1.44) and previous abortions (RRR=0.58, lower use of high FAS dosages among those with previous abortions) were significantly associated with the use of low FAS dosages in the periconceptional period. Unplanned pregnancy (RRR=2.66), previous abortions (RRR=0.68) and alcohol intake (RRR=1.42) were significantly associated with the use of high FAS dosages. These results were homogeneous among study areas (I²<50%).

The proportion of women using low FAS dosages after the periconceptional period was 55% and 17% of women took high FAS dosages after the periconceptional period. In this period, the mean daily intake of FAS was 511.7 µg/day for women classified as taking FAS dosages of 400–999 µg/day, 59.1 µg/day for women taking FAS dosages <400 µg/day and 4095.2 µg/day for women taking dosages of ≥1000 µg/day.

Table 3 shows multivariate analyses for all cohorts combined for the second period (4th–7th month). In the second period, only tobacco smoking was significantly associated with the use of high FAS dosages (RRR=0.67); no additional significant predictors of the use of low and high FAS dosages were found in the second period.

DISCUSSION
In this study, we show that a low percentage of pregnant women used FAS in preconception (23%), although the percentage of use increased to reach most of the women in the third month of pregnancy (86%). This pattern was consistent in the four areas of the study, although...
Table 1  Sociodemographic, lifestyle and obstetrics characteristics among pregnant women, from the INMA Project, Spain (2003–2008)

|                      | All cohorts (n=2332) | Asturias (n=434) | Guipuzcoa (n=521) | Sabadell (n=597) | Valencia (n=780) | p Value* |
|----------------------|---------------------|------------------|-------------------|------------------|------------------|-----------|
| Maternal age (>30 years), % (n) | 50.1 (1168) | 59.7 (259) | 55.1 (287) | 47.1 (281) | 43.2 (341) | <0.001 |
| Maternal education, % (n) |  |  |  |  |  |  |
| Primary school or less | 24.0 (560) | 16.8 (73) | 11.3 (59) | 28.0 (167) | 33.5 (261) | <0.001 |
| Secondary school | 41.6 (970) | 45.2 (196) | 35.3 (184) | 42.9 (256) | 42.8 (334) |  |
| University studies | 34.4 (802) | 38.0 (165) | 53.4 (278) | 29.1 (174) | 23.7 (185) |  |
| Paternal education, % (n) |  |  |  |  |  |  |
| Primary school or less | 35.5 (829) | 28.8 (125) | 24.4 (127) | 36.0 (215) | 46.4 (362) | <0.001 |
| Secondary school | 44.5 (1037) | 49.1 (213) | 50.5 (263) | 43.2 (258) | 38.8 (303) |  |
| University studies | 20.0 (466) | 22.1 (96) | 21.5 (131) | 20.8 (124) | 14.7 (115) |  |
| Tobacco smoking (during first trimester), % (n) | 18.1 (423) | 17.7 (77) | 11.9 (62) | 15.2 (91) | 24.7 (193) | <0.001 |
| Alcohol intake (during first trimester), % (n) | 29.9 (698) | 21.9 (95) | 36.1 (188) | 30.0 (179) | 30.3 (236) | <0.001 |
| Pre-pregnancy BMI in kg/m², % (n) |  |  |  |  |  |  |
| <25 | 73.3 (1710) | 69.1 (300) | 80.4 (419) | 72.2 (431) | 71.8 (560) | 0.001 |
| 25.0–29.9 | 18.7 (436) | 22.6 (98) | 14.6 (76) | 19.6 (117) | 18.6 (145) |  |
| ≥30 | 8.0 (186) | 8.3 (36) | 5.0 (26) | 8.2 (49) | 9.6 (75) |  |
| Unplanned pregnancy, n (%) | 16.7 (389) | 12.4 (54) | 9.6 (50) | 15.6 (93) | 24.6 (192) | <0.001 |
| Parity (≥1), n (%) | 43.3 (1009) | 38.2 (166) | 44.9 (234) | 43.2 (258) | 45.0 (351) | 0.112 |
| Previous abortions (yes), n (%) | 23.5 (549) | 23.7 (103) | 20.5 (107) | 25.5 (152) | 24.0 (187) | 0.270 |
| Private gynaecology (visit during first trimester), n (%) | 34.2 (797) | 50.2 (218) | 26.1 (136) | 29.5 (176) | 34.2 (267) | <0.001 |
| Dietary folate intake in µg/day 1st period¹, GM (mean, SD) | 293.5 (307.8, 96.3) | 305.0 (320.6, 103.5) | 302.5 (314.6, 90.3) | 285.3 (298.2, 90.8) | 287.6 (303.3, 99.3) | <0.001 |
| Folic acid supplements intake in µg/day 1st period¹, GM (mean, SD) | 450.9 (1029.4, 1626.6) | 610.0 (1180.8, 1613.0) | 585.5 (1331.9, 1788.1) | 353.4 (770.6, 1401.3) | 390.8 (941.0, 1643.7) | <0.001 |
| Dietary folate intake in µg/day 2nd period², GM (mean, SD) | 290.4 (304.7, 96.1) | 296.2 (312.1, 100.9) | 303.6 (313.0, 80.2) | 289.8 (302.4, 90.2) | 279.2 (296.8, 106.4) | 0.007 |
| Folic acid supplements intake in µg/day 2nd period², GM (mean, SD) | 631.1 (870.6, 1683.8) | 1014.7 (1975.2, 2267.5) | 666.4 (541.5, 1523.2) | 409.3 (216.1, 843.1) | 524.7 (977.6, 1561.5) | <0.001 |

¹: First period covers the months from preconception to the first trimester of pregnancy; ²: second period covers the months from the first to the third trimester.

*p Value from χ² test (categorical variables) and analysis of variance (continuous variables).

GM, Geometric mean.
significant differences emerged later; most of the women in Valencia and Asturias continued using FAS after the third month while most of the women in Guipuzcoa and Sabadell stopped using them. We also found that nearly one-third of the women used high dosages of FAS (≥1000 µg/day). The use of high FAS dosages in the first period, from preconception to the third month, was significantly associated with unplanned pregnancy and previous spontaneous abortion (lower use of high FAS dosages among those with previous abortions).

The mean daily dietary intake in the present study was similar to that reported in other European studies—below the recommended dietary intake for pregnant women. The unsatisfactory intake among pregnant women might be related to the lack of knowledge on food rich in this nutrient, as shown in a study conducted in a Mediterranean population, in which only 40% of respondents could identify one food rich in folate.

Regarding the use of FAS, the results of this study are in accordance with previous studies conducted in Spain and Portugal, where around 70% of pregnant women did not take FAS before pregnancy, and slightly higher than in other European studies. The considerable number of women who did not use FAS may be explained in part by the fact that they were not aware of being pregnant and, therefore, were not informed of the benefits of FAS at the beginning of their pregnancy. Based on our results, it seems that when women are aware of their pregnancy, they increase their use of FAS, particularly in the second and third month of pregnancy.

We observed two different patterns of FAS use after the third month in the four geographical areas of the study. Women in Valencia and Asturias continued with the use of FAS while women in Guipuzcoa and Sabadell mostly abandoned the use of supplements. We have no clear explanation for the two different patterns of FAS use observed between areas, although it could be related, in part, to the different policy statements of regional scientific societies about FAS use, as has been observed for other nutrients such as iodine supplementation.

The large number of pregnant women reporting the use of high FAS dosages during pregnancy has also been reported in two other previous studies in Spain. A possible cause could be related to medical reasons since women with diabetes, epilepsy or history of NTDs before pregnancy are usually recommended to take FAS dosages of 5000 µg/day in the periconceptional period. However, in our study, the number of women with these pathologies was low (<1%). Moreover, the use of these high dosages of FAS was unnecessarily maintained after the third month of pregnancy. The percentage of women taking high dosages of FAS was unnecessarily maintained after the third month of pregnancy. The percentage of women taking high dosages of FAS in this study was lower than that observed in a previous study in Spain, which may be explained in part by the debate and the controversy on the consequences of a higher than recommended FA supplementation. We believe that the percentage of women taking high FAS dosages still remains high, and further studies are needed to monitor the use of FAS during pregnancy and the potential harmful effects that have been shown recently.

Several associations were found with the use of high FAS dosages. The positive association with unplanned pregnancy and the negative association with previous spontaneous abortion have been found in other

---

Figure 1  Folic acid supplements use among 2422 participants in all cohorts of the INMA Project, Spain (2003-2008). Percentage by months of pregnancy.
Women who have planned their pregnancy and those who had undergone a previous spontaneous abortion may have higher awareness of the benefits of recommended intake and FAS dosages (400–999 µg/day) in pregnancy. The association with tobacco smoking, alcohol intake and parity found in our study have also been found in other studies.19 42 43 It is possible that pregnant women with better lifestyles had a better compliance with the recommended dosages of FAS than those with less healthy lifestyles (e.g., alcohol drinkers). However, more studies are required to confirm these associations with the use of high dosages of FAS during the periconceptional period in order to implement public health actions.

This study has several strengths. The prospective design minimises selection and recall bias. We assessed dietary folate intake and FAS use prospectively in different geographical areas of Spain with a wide range of consumption, using a validated FFQ in the same study population. Our study also has some limitations. This was a population-based cohort study and non-participation might limit the generalisability of some results; however, when the sociodemographic characteristics of participants and non-participants were compared, participants were more likely to be younger, better educated, and have a higher socioeconomic status. The study was also limited by the use of self-reported data for some variables, such as alcohol and tobacco use, which may introduce bias.

| Women who took FAS, n (%) | Folic acid supplement use (in µg/day) during the first period† | Maternal age, (years) | Maternal education | Paternal education | Tobacco smoking† | Alcohol consumption† | Pre-pregnancy BMI | Planned pregnancy | Parity | Previous abortions | Private gynaecologist† |
|--------------------------|----------------------------------|----------------------|-------------------|-------------------|-----------------|-------------------|-----------------|-----------------|--------|------------------|---------------------|
|                          | 400–999 (mean=433.0)             | <400, included non use (mean=141.8) | ≥1000 (mean=3104.6) |
|                           | 329 (14%)                        | 1336 (57%)           | 666 (29%)         |
|                           | n                                | n                   | RRR* (95% CI) I², %‡ | n                   | RRR* (95% CI) I², %‡ |
| Maternal age, (years)     |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| ≤30                      | 161                               | 722                 | 1.00              | 281                | 1.00            |                   |                 |                 |        |                   |                     |
| >30                      | 168                               | 614                 | 0.90 (0.58 to 1.40) | 58.4               | 385             | 1.31 (0.82 to 2.10) | 58.5           |                 |        |                   |                     |
| Maternal education       |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| Primary school or less    | 65                                | 373                 | 1.00              | 122                | 1.00            |                   |                 |                 |        |                   |                     |
| Secondary school         | 124                               | 563                 | 1.06 (0.73 to 1.52) | 0.0                | 283             | 1.31 (0.88 to 1.94) | 0.0            |                 |        |                   |                     |
| University studies        | 140                               | 400                 | 0.66 (0.44 to 0.98) | 27.3               | 261             | 0.91 (0.59 to 1.39) | 24.4           |                 |        |                   |                     |
| Paternal education       |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| Primary school or less    | 96                                | 525                 | 1.00              | 208                | 1.00            |                   |                 |                 |        |                   |                     |
| Secondary school         | 164                               | 557                 | 0.70 (0.51 to 0.95) | 0.0                | 316             | 0.82 (0.59 to 1.15) | 0.0            |                 |        |                   |                     |
| University studies        | 69                                | 254                 | 0.97 (0.65 to 1.45) | 0.0                | 142             | 1.00 (0.65 to 1.54) | 0.0            |                 |        |                   |                     |
| Tobacco smoking†         |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| No                       | 289                               | 1061                | 1.00              | 558                | 1.00            |                   |                 |                 |        |                   |                     |
| Yes                      | 40                                | 275                 | 1.63 (1.11 to 2.39) | 0.0                | 108             | 1.36 (0.90 to 2.07) | 0.0            |                 |        |                   |                     |
| Alcohol consumption†     |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| No                       | 251                               | 923                 | 1.00              | 460                | 1.00            |                   |                 |                 |        |                   |                     |
| Yes                      | 78                                | 413                 | 1.40 (1.02 to 1.92) | 39.1               | 206             | 1.42 (1.01 to 1.98) | 19.2           |                 |        |                   |                     |
| Pre-pregnancy BMI         |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| <25                      | 241                               | 969                 | 1.00              | 499                | 1.00            |                   |                 |                 |        |                   |                     |
| 25–29.9                  | 60                                | 253                 | 0.95 (0.67 to 1.33) | 0.0                | 123             | 0.90 (0.62 to 1.30) | 19.9           |                 |        |                   |                     |
| ≥30                      | 28                                | 114                 | 0.89 (0.55 to 1.44) | 12.4               | 44              | 0.79 (0.46 to 1.36) | 0.0            |                 |        |                   |                     |
| Planned pregnancy        |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| Yes                      | 312                               | 1051                | 1.00              | 579                | 1.00            |                   |                 |                 |        |                   |                     |
| No                       | 17                                | 285                 | 4.20 (2.47 to 7.12) | 5.0                | 87              | 2.66 (1.52 to 4.65) | 0.0            |                 |        |                   |                     |
| Parity                   |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| 0                        | 209                               | 744                 | 1.00              | 369                | 1.00            |                   |                 |                 |        |                   |                     |
| ≥1                       | 120                               | 592                 | 1.44 (1.08 to 1.91) | 0.0                | 297             | 1.33 (0.98 to 1.80) | 0.0            |                 |        |                   |                     |
| Previous abortions       |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| No                       | 231                               | 1047                | 1.00              | 504                | 1.00            |                   |                 |                 |        |                   |                     |
| Yes                      | 98                                | 289                 | 0.58 (0.43 to 0.77) | 45.5               | 162             | 0.68 (0.50 to 0.94) | 42.0           |                 |        |                   |                     |
| Private gynaecologist†   |                                   |                     |                   |                   |                 |                   |                 |                 |        |                   |                     |
| No                       | 189                               | 923                 | 1.00              | 423                | 1.00            |                   |                 |                 |        |                   |                     |
| Yes                      | 140                               | 413                 | 0.78 (0.52 to 1.17) | 53.0               | 243             | 0.88 (0.42 to 1.88) | 84.2§          |                 |        |                   |                     |

*Cohort-specific multinomial logistic models were combined using meta-analysis, the models were adjusted by all variables in the table.†During the periconceptional stage from the preconception to the third month.‡We used the results from fixed effect meta-analysis model when I² was <50% and from the random effects meta-analysis model when I² was >50%.§P Cochran <0.05 from test of heterogeneity.

BMI, body mass index; RRR, relative risk ratio.
compared, no significant differences were found except for working status and age, with a higher proportion of working women and slightly higher mean age among participants. Despite some study limitations, if confirmed, our findings should have implications for future public health policies and strategies to promote adequate use of FAS at the recommended dosages during the periconceptional period, and to prevent the use of unnecessary dosages in other periods.

In conclusion, this study shows that the use of FAS among pregnant women in Spain is far from satisfactory. Most women did not follow recommendations for FAS during pregnancy, using dosages either below or above the current recommendation. Previous pregnancies, tobacco smoking, alcohol consumption, unplanned pregnancies and no previous abortions were associated with FAS use below 400 µg/day in the periconceptional period. Alcohol consumption, unplanned pregnancy and previous spontaneous abortion were also predictors of the use of high dosages of FAS at this initial stage. These findings should be further monitored; meanwhile, public health strategies should be planned to increase public awareness of the appropriate periconceptional use of FAS and to encourage health professionals to prevent the use of FAS dosages above or below the current recommendations.

| Table 3  | Pooled RRR* and 95% CI of folic acid supplements doses in the second period† of pregnancy among pregnant women, from the INMA Project, Spain (2003–2008) |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| **Women who took FAS, n (%)** | **Folic acid supplement use (in µg/day) during the second period†** |
| | 400–999 (mean=511.7) | 400, included non use (mean=59.1) | ≥1000 (mean=4095.2) |
| | n | RRR* (95% CI) | I² (%) ‡ | n | RRR* (95% CI) | I² (%) ‡ |
| Maternal age (years) | | | | | | |
| ≤30 | 343 | 653 | 1.00 | 164 | 1.00 | |
| >30 | 314 | 622 | 1.05 (0.61 to 1.82) | 77.2§ | 230 | 1.54 (0.92 to 2.59) | 61.8§ |
| Maternal education | | | | | | |
| Primary school or less | 194 | 284 | 1.00 | 82 | 1.00 | |
| Secondary school | 274 | 523 | 1.29 (0.97 to 1.72) | 0.0 | 168 | 1.26 (0.88 to 1.80) | 0.0 |
| University studies | 189 | 468 | 1.30 (0.92 to 1.85) | 0.0 | 144 | 1.20 (0.54 to 2.66) | 65.4§ |
| Paternal education | | | | | | |
| Primary school or less | 254 | 441 | 1.00 | 133 | 1.00 | |
| Secondary school | 282 | 568 | 0.89 (0.69 to 1.15) | 0.0 | 182 | 0.94 (0.68 to 1.29) | 0.0 |
| University studies | 121 | 266 | 0.78 (0.54 to 1.12) | 0.0 | 79 | 0.80 (0.52 to 1.22) | 25.3 |
| Tobacco smoking‡ | | | | | | |
| No | 512 | 1088 | 1.00 | 332 | 1.00 | |
| Yes | 145 | 187 | 0.70 (0.42 to 1.18) | 61.7¶ | 62 | 0.67 (0.47 to 0.96) | 8.1 |
| Alcohol consumption† | | | | | | |
| No | 426 | 767 | 1.00 | 252 | 1.00 | |
| Yes | 231 | 508 | 1.01 (0.80, 1.28) | 0.0 | 142 | 1.09 (0.82 to 1.45) | 0.0 |
| Pre-pregnancy BMI | | | | | | |
| <25 | 456 | 970 | 1.00 | 281 | 1.00 | |
| 25–29.9 | 138 | 217 | 0.82 (0.62 to 1.09) | 0.0 | 80 | 0.89 (0.63 to 1.25) | 0.0 |
| ≥30 | 63 | 88 | 0.70 (0.47 to 1.06) | 11.5 | 33 | 0.87 (0.53 to 1.43) | 0.0 |
| Planned pregnancy | | | | | | |
| Yes | 531 | 1073 | 1.00 | 336 | 1.00 | |
| No | 126 | 202 | 1.05 (0.78 to 1.41) | 0.0 | 58 | 0.90 (0.61 to 1.32) | 0.0 |
| Parity | | | | | | |
| 0 | 381 | 717 | 1.00 | 223 | 1.00 | |
| ≥1 | 276 | 558 | 1.08 (0.85 to 1.38) | 35.5 | 171 | 0.99 (0.74 to 1.33) | 76.3§ |
| Previous abortions | | | | | | |
| No | 504 | 974 | 1.00 | 301 | 1.00 | |
| Yes | 153 | 301 | 1.07 (0.82 to 1.41) | 7.8 | 93 | 0.95 (0.69 to 1.31) | 10.9 |
| Private gynaecologist¶ | | | | | | |
| No | 404 | 880 | 1.00 | 245 | 1.00 | |
| Yes | 253 | 395 | 0.88 (0.60 to 1.27) | 54.9 | 149 | 0.79 (0.28 to 2.21) | 91.3§ |

*Cohort-specific multinomial logistic models were combined using meta-analysis, the models were adjusted by all variables in the table.
†Second period covers the months from the fourth to the seventh month of pregnancy.
‡We used the results from fixed effect meta-analysis model when I² was <50% and from the random effects meta-analysis model when I² was >50%.
§p Cochran <0.05 from test of heterogeneity.
¶During the periconceptional stage (first period) from the preconception to the third month.
BMI, body mass index; RRR, relative risk ratio.
Acknowledgements The authors appreciate the English revisions made by Mr Jonathan Whitehead.

Collaborators For a complete list of INMA project researchers: http://www.proyectoimma.org/presentacion-imma/listado-investigadores/en_listado-investigadores.html.

Contributors EMN-M and JV conceived the study. EMN-M, DV-G and JV conducted the data analysis and prepared the manuscript; MGdh contributed to the conceptual approach and manuscript preparation; MM, IR, EM and LS-M contributed to the data interpretation and manuscript preparation; DG-M and MGdh assisted with the nutritional data and provided feedback; JV designed the FFQ and contributed to manuscript preparation; JJ, JI, AT, MR and JV supervised the data collection, obtained funding, and helped with data interpretation and manuscript preparation. EMN-M, DV-G, MGdh, DG-M, EM, JJ, IR, AT, LS-M, MR and JV were responsible for critical revision of the manuscript for important intellectual content.

Funding This study was funded by grants from Instituto de Salud Carlos III and Spanish Ministry of Health (Red INMA G03/176; CB06/02/0041; FIS 97/0586; 00/0021–2, P0167156; PS0901958; FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314, 08/02642; FIS-Pi041436, FIS-Pi081151, FIS-Pi08/0687; FIS-Pi09/0090, FIS-Pi042018, FIS-Pi09 02311, FIS Pi11/01007, FISPI13/02429). Universidad de Oviedo, Conselleria de Sanitat Generalitat Valenciana, Generalitat de Catalunya-CIRIT 1999SRR 00241. Department of Health of the Basque Government (2005111093 and 2009111069) and the Provincial Government of Guipuzcoa (DFG06/004 and DFG08/001).

Competing interests None declared.

Patient consent Obtained.

Ethics approval This study was conducted with the approval of the The Institut Municipal d’Investigació Médica (Barcelona), the Asturian Regional Ethics Committee (Asturias), Hospital La Fe (Valencia) and Hospital Donostia (Gipuzkoa).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131–7.

2. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832–5.

3. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington DC: The National Academies Press, 1998.

4. Grupo de trabajo de la Guía de práctica clínica de atención en el embarazo y puerperio. Ministerio de Sanidad, Servicios Sociales e Igualdad. Agencia de Evaluación de Tecnologías Sanitarias de la Seguridad Social. 2014, Guías de Práctica Clínica en el SNS: AETSA 2011/10. http://www.juntadeandalucia.es/salud/servicios/contenidos/nuevaavesta/sa5/AETSA_2011_10_GPO_Embazoaro.pdf (accessed Jul 2014).

5. Pastor-Valero M, Navarrete-Muñoz EM, Rebagliato M, et al. Periconceptional folic acid supplementation and anthropometric measures at birth in a cohort of pregnant women in Valencia, Spain. Br J Nutr 2011;105:1532–60.

6. Takimoto H, Hayashi F, Kusama K, et al. Elevated maternal serum folate in the third trimester and reduced fetal growth: a longitudinal study. J Nutr Sci Vitaminol 2011;57:130–7.

7. Zetra-vaan der Woude PA, De Waa ME, Hoek A, et al. Maternal high-dose folic acid during pregnancy and asthma medication in the offspring. Pharmacoepidemiol Drug Saf 2014;23:1059–65.

8. Valera-Gran D, Garcia de la Hera M, Navarrete-Muñoz EM, et al. Folic Acid supplements during pregnancy and child psychomotor development after the first year of life. JAMA Pediatr 2014;168: e142611.

9. Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals. Lancet 2013;381:1029–36.

10. Tamura T, Picciano MF. Folate and human reproduction. Am J Clin Nutr 2006;83:993–1016.

11. Mantovani F, Filippini F, Bortolus R, et al. Folic acid supplementation and preterm birth: results from observational studies. BioMed Res Int 2014;481914.

12. Rothen R, Magnus P, Schjølberg S, et al. Folic acid supplements in pregnancy and severe language delay in children. JAMA 2011;306:1566–73.

13. Surin P, Roth C, Bresnahan M, et al. Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. JAMA 2013;309:570–7.

14. Brown SB, Reeves KW, Bertone-Johnson ER. Maternal folate exposure in pregnancy and childhood asthma and allergy: a systematic review. Nutr Rev 2014;72:55–64.

15. Crider KS, Cordero AM, QI YP, et al. Prenatal folic acid and risk of asthma in children: a systematic review and meta-analysis. Am J Clin Nutr 2013;98:1272–81.

16. Motoyama-Nazé Frias ML, Grupo de trabajo del ECEMC [folic acid dose in the prevention of congenital defects]. Med Clin (Barc) 2007;128:809–16.

17. Timmermans S, Jaddoe VWV, Mackenbach JP, et al. Determinants of folic acid use in early pregnancy in a multi-ethnic urban population in the Netherlands: the Generation R study. Prev Med 2008;47:427–32.

18. Pauk E, Császár J, Kozinszky Z, et al. Preconceptional and prenatal predictors of folic acid intake in Hungarian pregnant women. Eur J Obstet Gynecol Reprod Biol 2009;145:49–52.

19. Cueto HT, Riis AH, Hartch E, et al. Predictors of preconceptional folic acid or multivitamin supplement use: a cross-sectional study of Danish pregnancy planners. Clin Epidemiol 2012;4:259–65.

20. Nilsen RM, Vollset SE, Gjessing HK, et al. Paterns and predictors of folic acid supplement use among pregnant women: the Norwegian Mother and Child Cohort Study. Am J Clin Nutr 2006;84:1134–41.

21. Guxens M, Ballester F, Espada M, et al. Cohort profile: the INMA—Infancia y Medio Ambiente—(Environment and Childhood) Project. Int J Epidemiol 2012;41:930–40.

22. Navarrete-Muñoz EM, Gimenez-Monzo D, Garcia de La Hera M, et al. Folic acid intake from diet and supplements in a population of pregnant women in Valencia, Spain. Med Clin (Barc) 2010;135:837–43.

23. Willett WC, Sampson L, Stampfer MJ, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51–65.

24. Vioque J, Navarrete-Munoz EM, Gimenez-Monzó D. Reproducibility and reliability of a food frequency questionnaire among pregnant women in a Mediterranean area. Nutr J 2013;12:26.

25. US Department of Agriculture, Agricultural Research Service. USDA National Nutrient Database for Standard Reference, Release 21. http://www.nal.usda.gov/fnic/foodcomp/Data/SR21/nutrlist/sr21a306.pdf (accessed Nov 2008).
26. Palma I, Farran A, Cantós D. Tablas de Composición de Alimentos por Medidas Caseras de Consumo Habitual en España. CESNID. Madrid: McGraw-Hill Interamerican, 2008.
27. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.
28. Rogers I, Emmett P. Diet during pregnancy in a population of pregnant women in South West England. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. Eur J Clin Nutr 1998;52:742–8.
29. Pinto E, Barros H, dos Santos Silva I. Dietary intake and nutritional adequacy prior to conception and during pregnancy: a follow-up study in the north of Portugal. Public Health Nutr 2009;12:922–31.
30. Coll O, Pisa S, Palacio M, et al. Awareness of the use of folic acid to prevent neural tube defects in a Mediterranean area. Eur J Obstet Gynecol Reprod Biol 2004;115:173–7.
31. Martinez-Frias ML, Rodriguez-Pinilla E, Bermejo E. [Analysis of the Spanish situation regarding folic acid/calcic folinate consumption for birth defects prevention]. Med Clin (Barc) 2003;121:772–5.
32. Cuervo M, Sayon-Orea C, Santiago S, et al. Dietary and health profiles of Spanish women in preconception, pregnancy and lactation. Nutrients 2014;6:4434–51.
33. Donnay S, Arena J, Lucas A, et al. Position statement of the working group on disorders related to iodine deficiency and thyroid dysfunction of the Spanish Society of Endocrinology and Nutrition. Endocrinol Nutr 2014;61:27–34.
34. Santíà™-Gimeno G, Ferreros I, Librero J, et al. Characterization of folate supplementation in pregnancy, based on a combination of health information systems. Gac Sanit 2012;26:512–18.
35. Lucock M. Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol Genet Metab 2000;71:121–38.
36. Martinez-Frias ML, Rodriguez-Pinilla E, Mejias C, et al. Primary prevention of neural tube defects: folic acid or levofolate acid? Med Clin (Barc) 2002;118:358–9.
37. Morin P, De Wals P, Noisel X, et al. Pregnancy planning and folic acid supplement use: results from a survey in Quebec. Prev Med 2002;35:143–9.
38. Morin P, De Wals P, St-Cyr-Tribble D, et al. Pregnancy planning: a determinant of folic acid supplements use for the primary prevention of neural tube defects. Can J Public Health Rev 2002;93:259–63.
39. Braekke K, Staff AC. Periconceptional use of folic acid supplements in Oslo. Acta Obstet Gynecol Scand 2003;82:620–7.
40. Knudsen VK, Orozova-Bekkevold I, Rasmussen LB, et al. Low compliance with recommendations on folic acid use in relation to pregnancy: is there a need for fortification? Public Health Nutr 2004;7:843–50.